Agilent Technologies Inc. (NYSE: A) today announced it has completed the acquisition of the BioSystem Development business. BioSystem Development is a privately held company that develops and manufactures the AssayMAP Microchromatography platform to meet the analytical needs of the life sciences industry.
Agilent announced the signing of an acquisition agreement on Dec. 1. Financial details of the transaction were not disclosed.
As life science discovery and development continues to move toward a better understanding of biological responses to disease, and has an increased emphasis on protein-based therapeutics by pharmaceutical companies, the need for automated, quality protein sample preparation and analysis has become critical.
BioSystem Development's AssayMAP platform, based on disposable microchromatography cartridges, enables for the first time, automation of complex, multi-step sample preparation workflows. These include protein purification, characterization and analysis solutions for bioprocess development, biomarker identification and analysis, as well as a variety of other life science research applications.
The acquisition formalizes and streamlines the ongoing collaboration between BioSystem Development and Agilent to combine AssayMAP technology with Agilent's industry-leading automated liquid handling platforms, to reduce discovery and development time and increase lab efficiency.
Study reveals key protein's role in balancing immune response to viral infections